Biotransformation of 4'-hydroxychalcone substrates

The biotransformation of 4'-hydroxychalcone substrates refers to the enzymatic and chemical modifications of 4'-hydroxychalcone, a phenolic compound used as a model scaffold in pharmacology and biotechnology. This term does not represent a discrete therapeutic target or receptor, but rather a sequence of metabolic reactions mediated by various enzymes, including enoate reductases (Old Yellow Enzyme family), glucosyltransferases, and cytochrome P450s [PubChem, PMID: 33053894]. In microbial systems such as Yarrowia lipolytica or Aspergillus niger, the process typically involves the selective reduction of the alpha,beta-unsaturated double bond to produce 4'-hydroxydihydrochalcone, a bioactive derivative found in medicinal plants [PMID: 38239523, PMID: 15158933]. In mammalian systems, the molecule is primarily metabolized via conjugation, such as glucuronidation, to facilitate excretion [PubChem]. Although the biotransformation process itself is not a drug target, the substrate 4'-hydroxychalcone exhibits significant pharmacological activities, most notably acting as an inhibitor of the NF-kappaB pathway through proteasome inhibition [PMID: 21703248]. Characterizing these metabolic pathways is essential in drug discovery to optimize the bioavailability and safety profiles of chalcone-based therapeutic candidates [BenchChem].

Other names

4'-Hydroxychalcone metabolismMicrobial conversion of 4'-hydroxychalconeEnzymatic reduction of chalconesBiotransformation of p-cinnamoylphenol

The process involves the selective reduction of the chalcone double bond by ene-reductases and the conjugation of hydroxyl groups by transferases.